Stimulation with TLR7 agonist impairs the response of CAL-1 to GSK3326595. Gene expression of (A) IFITs and (B) IRFs after stimulation with imiquimod. (C) Schematic illustration of the dual treatment regimen. (D) Phenotypic analysis of BPDCN surface markers after dual treatment (imiquimod + GSK595). (E) CAL-1 growth after stimulation with imiquimod and concurrent treatment with GSK595. (F) Lack of apoptosis activation upon treatment in imiquimod-stimulated cells. Gene expression of (G) BCL-2, (H) IFIT1, and (I) IRF7 after imiquimod stimulation and GSK595 treatment (normalized to WT DMSO). Data are shown as mean ± standard error of the mean of 3 independent experiments. *P < .05; **P < .01; P < .001.